Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings relevant to Helius Medical Tech WT 26 (HSDTW), a warrant security associated with Helius Medical Technologies, Inc. The company files under the name Helius Medical Technologies, Inc., and its Class A common stock is listed on The Nasdaq Stock Market LLC under the symbol HSDT, as stated in multiple Form 8-K reports.
In recent Form 8-K filings, the company reports material definitive agreements involving private offerings of common stock, pre-funded warrants, stapled warrants, and warrants issued to strategic advisors. These filings describe cash and cryptocurrency-based offerings with accredited investors, where consideration may be paid in U.S. dollars, USDC, USDT, or Solana (SOL) tokens. The documents also outline lock-up provisions, stockholder approval requirements for the exercise of certain warrants, and registration rights for the resale of underlying shares.
For investors analyzing HSDTW and related securities, key filings include Form 8-K items on unregistered sales of equity securities, securities purchase or subscription agreements, strategic advisor agreements, and amendments to the company’s authorized share capital. The filings further state that net proceeds from the offerings are intended to fund the acquisition of SOL through open market purchases, support Solana treasury operations, and provide working capital and general corporate funds, subject to specified limitations.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that explain the core terms of each document, highlight important conditions affecting warrants and common stock, and help readers understand complex capital structure changes. Real-time updates from EDGAR, along with structured access to Form 8-K items and related exhibits, allow users to review how Helius Medical Technologies, Inc. discloses its financing activities and warrant arrangements that underpin the HSDTW security.
Solana Co director Sherrie L. Perkins reported equity compensation awards. She received a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. She was also granted 2,180 shares of Class A Common Stock as restricted stock units under the 2022 Equity Incentive Plan. According to the awards’ terms, 75% of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, subject to her continued service. Following the stock grant, she directly holds 92,220 shares of Class A Common Stock.
Solana Co director Paul Buckman received new equity awards as part of his compensation. He was granted a stock option covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036.
He also received 2,180 shares of Class A Common Stock, increasing his direct holdings to 92,004 shares. Both the option and restricted stock units vest 75% on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, contingent on his continued service.
Solana Co director Edward M. Straw received equity awards as part of his compensation. He was granted stock options for 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock via restricted stock units. Seventy-five percent of both the RSUs and options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, conditional on his continued service. Following the stock grant, he directly holds 92,291 Class A Common shares.
Solana Co director Walter Blane received new equity awards in the form of stock options and restricted stock units. He was granted stock options covering 23,529 shares of Class A Common Stock at an exercise price of $6.881 per share, expiring on March 30, 2036. He also received 2,180 shares of Class A Common Stock from a grant classified as a restricted stock unit award. According to the award terms, 75% of both the RSUs and the options vested on March 31, 2026, with the remaining 25% scheduled to vest on June 30, 2026, if he continues in service.
Solana Company (HSDT) has transformed into a listed digital asset treasury focused on acquiring and holding Solana tokens (SOL), aiming to maximize SOL per share through capital markets activity, staking and selective DeFi strategies. The treasury is expected to remain highly concentrated in SOL, with significant portions staked via institutional custodians and validators to earn yield, while managing liquidity through unstaked SOL, liquid staking tokens, cash and stablecoins.
The company also maintains, to a lesser extent, its legacy neurotechnology business built around the PoNS medical device, which is cleared or authorized for multiple gait and balance indications in the U.S. and Canada and has been commercially available in those markets for several years.
Kathmere Capital Management, LLC reported beneficial ownership of 4,594,960 shares of Class A Common Stock of Solana Co, equal to 8.7% of the class as of 02/24/2026. The filing lists Kathmere with sole dispositive power over 4,594,960 shares and no voting power reported.
Solana Company, formerly known as Helius Medical Technologies, Inc., reported its current capital structure. As of February 20, 2026, the Company has 52,802,604 shares of common stock issued and outstanding. In addition, it has pre-funded warrants outstanding that are exercisable for 23,930,181 shares of common stock.
Polar Asset Management Partners Inc., an Ontario-based investment manager, reported beneficial ownership of Class A common stock of Solana Co. Polar is the investment advisor to Polar Multi-Strategy Master Fund, which directly holds the securities.
Polar reports beneficial ownership of 2,413,279 shares, including 2,179,916 shares issuable upon exercising warrants, representing 5.8% of Solana Co’s Class A common stock as of the event date. Polar has sole voting and dispositive power over these shares and certifies they were acquired and are held in the ordinary course of business, not to change or influence control of Solana Co.
Solana Rocket Holdings Limited and CHUNG Wai Shing have amended their ownership report for Solana Co. They jointly report beneficial ownership of 4,192,186 shares of Class A common stock, representing 9.99% of the company as of December 31, 2025.
The position is made up of 3,529,754 common shares plus pre-funded warrants for up to 10,743,213 shares and cash stapled warrants for up to 14,823,426 shares, all held by Solana Rocket. A “Beneficial Ownership Blocker” prevents them from exercising warrants if it would push their stake above 9.99%.
The 9.99% figure is calculated using 41,301,400 shares outstanding as of November 17, 2025, plus 662,432 shares issuable on partial warrant exercise. Voting and dispositive power over all 4,192,186 shares is reported as shared.
Helius Medical Technologies, Inc. filed a current report to furnish information under Regulation FD. The company stated that on September 22, 2025 it issued a press release and attached this release as Exhibit 99.1 to the report. The filing does not describe the contents of the press release, instead directing readers to the attached exhibit for details.